Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

P. Conte, A. Frassoldati, G. Bisagni, A.A. Brandes, M. Donadio, O. Garrone, F. Piacentini, L. Cavanna, F. Giotta, M. Aieta, V. Gebbia, A. Molino, A. Musolino, A. Ferro, R. Maltoni, S. Danese, C. Zamagni, A. Rimanti, K. Cagossi, A. RussoP. Pronzato, F. Giovanardi, G. Moretti, L. Lombardo, A. Schirone, A. Beano, L. Amaducci, E.A. Bajardi, R. Vicini, S. Balduzzi, R. D'Amico, V. Guarneri, Reader study level-I, level-II Groups

Research output: Contribution to journalArticle

Abstract

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age ≤35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)
Original languageEnglish
Pages (from-to)2328-2333
Number of pages6
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
Issue number12
DOIs
Publication statusPublished - Dec 2018

Fingerprint

Combination Drug Therapy
Disease-Free Survival
Breast Neoplasms
Drug Therapy
Anthracyclines
Blood Vessels
Trastuzumab
Hormones
Therapeutics

Cite this

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. / Conte, P.; Frassoldati, A.; Bisagni, G.; Brandes, A.A.; Donadio, M.; Garrone, O.; Piacentini, F.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Molino, A.; Musolino, A.; Ferro, A.; Maltoni, R.; Danese, S.; Zamagni, C.; Rimanti, A.; Cagossi, K.; Russo, A.; Pronzato, P.; Giovanardi, F.; Moretti, G.; Lombardo, L.; Schirone, A.; Beano, A.; Amaducci, L.; Bajardi, E.A.; Vicini, R.; Balduzzi, S.; D'Amico, R.; Guarneri, V.; level-I, Reader study; Groups, level-II.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, No. 12, 12.2018, p. 2328-2333.

Research output: Contribution to journalArticle

Conte, P, Frassoldati, A, Bisagni, G, Brandes, AA, Donadio, M, Garrone, O, Piacentini, F, Cavanna, L, Giotta, F, Aieta, M, Gebbia, V, Molino, A, Musolino, A, Ferro, A, Maltoni, R, Danese, S, Zamagni, C, Rimanti, A, Cagossi, K, Russo, A, Pronzato, P, Giovanardi, F, Moretti, G, Lombardo, L, Schirone, A, Beano, A, Amaducci, L, Bajardi, EA, Vicini, R, Balduzzi, S, D'Amico, R, Guarneri, V, level-I, RS & Groups, L-II 2018, 'Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, no. 12, pp. 2328-2333. https://doi.org/10.1093/annonc/mdy414
Conte, P. ; Frassoldati, A. ; Bisagni, G. ; Brandes, A.A. ; Donadio, M. ; Garrone, O. ; Piacentini, F. ; Cavanna, L. ; Giotta, F. ; Aieta, M. ; Gebbia, V. ; Molino, A. ; Musolino, A. ; Ferro, A. ; Maltoni, R. ; Danese, S. ; Zamagni, C. ; Rimanti, A. ; Cagossi, K. ; Russo, A. ; Pronzato, P. ; Giovanardi, F. ; Moretti, G. ; Lombardo, L. ; Schirone, A. ; Beano, A. ; Amaducci, L. ; Bajardi, E.A. ; Vicini, R. ; Balduzzi, S. ; D'Amico, R. ; Guarneri, V. ; level-I, Reader study ; Groups, level-II. / Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29, No. 12. pp. 2328-2333.
@article{1e18536dbbcd4528ae10332a4fc32bf6,
title = "Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡",
abstract = "Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20{\%}, age ≤35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)",
author = "P. Conte and A. Frassoldati and G. Bisagni and A.A. Brandes and M. Donadio and O. Garrone and F. Piacentini and L. Cavanna and F. Giotta and M. Aieta and V. Gebbia and A. Molino and A. Musolino and A. Ferro and R. Maltoni and S. Danese and C. Zamagni and A. Rimanti and K. Cagossi and A. Russo and P. Pronzato and F. Giovanardi and G. Moretti and L. Lombardo and A. Schirone and A. Beano and L. Amaducci and E.A. Bajardi and R. Vicini and S. Balduzzi and R. D'Amico and V. Guarneri and level-I, {Reader study} and level-II Groups",
note = "cited By 0",
year = "2018",
month = "12",
doi = "10.1093/annonc/mdy414",
language = "English",
volume = "29",
pages = "2328--2333",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

AU - Conte, P.

AU - Frassoldati, A.

AU - Bisagni, G.

AU - Brandes, A.A.

AU - Donadio, M.

AU - Garrone, O.

AU - Piacentini, F.

AU - Cavanna, L.

AU - Giotta, F.

AU - Aieta, M.

AU - Gebbia, V.

AU - Molino, A.

AU - Musolino, A.

AU - Ferro, A.

AU - Maltoni, R.

AU - Danese, S.

AU - Zamagni, C.

AU - Rimanti, A.

AU - Cagossi, K.

AU - Russo, A.

AU - Pronzato, P.

AU - Giovanardi, F.

AU - Moretti, G.

AU - Lombardo, L.

AU - Schirone, A.

AU - Beano, A.

AU - Amaducci, L.

AU - Bajardi, E.A.

AU - Vicini, R.

AU - Balduzzi, S.

AU - D'Amico, R.

AU - Guarneri, V.

AU - level-I, Reader study

AU - Groups, level-II

N1 - cited By 0

PY - 2018/12

Y1 - 2018/12

N2 - Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age ≤35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)

AB - Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age ≤35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)

U2 - 10.1093/annonc/mdy414

DO - 10.1093/annonc/mdy414

M3 - Article

VL - 29

SP - 2328

EP - 2333

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -